EUVIMEDEUVIMED entdecken
EditorialKohortenstudieOpen Access

Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2− metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China

Nino Balanchivadze, Nicholas J Robert

Translational Breast Cancer Research · 2023-10 · 4 · 32-32

DOI: 10.21037/tbcr-23-45 ↗

Kurz gefasst

Editorial in der Zeitschrift Translational Breast Cancer Research, 2023-10. Verfasst von Nino Balanchivadze und 1 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Oncology Associates/US Oncology Network, Norfolk, VA, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Hormone receptor-positive human epidermal growth factor receptor-2-negative met…abemaciclibpersonalized medicinetucidinostat

Autor:innen und Institutionen

  • Virginia Oncology Associates/US Oncology Network, Norfolk, VA, USA.
  • Ontada, Boston, MA, USA.

Zitieren

APA

Balanchivadze, N., & Robert, N. J. (2023). Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2− metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China. Translational Breast Cancer Research, 4, 32-32. https://doi.org/10.21037/tbcr-23-45

Vancouver

Balanchivadze N, Robert NJ. Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2− metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China. Translational Breast Cancer Research. 2023;4:32-32. doi:10.21037/tbcr-23-45

BibTeX
@article{Balanchivadze2023,
  author = {Balanchivadze, Nino and Robert, Nicholas J},
  title = {Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2− metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China},
  journal = {Translational Breast Cancer Research},
  year = {2023},
  volume = {4},
  pages = {32--32},
  doi = {10.21037/tbcr-23-45}
}
Kostenlos starten →